By: Lifestyle Desk | New Delhi | Published: July 7, 2020 6:33:51 pm Rowling wrote a long tread defending herself. (Photo: JK Rowling/Facebook)

It will probably be a while for JK Rowling to extricate herself from the growing controversy she finds herself embroiled in. Recently, the Harry Potter author faced fresh heat on one of her tweets that suggested transgender hormone therapy is a variant of conversion therapy for young gay people..

It all started when a Twitter user made a claim that the author had allegedly liked a tweet that compared prescribed hormones to antidepressants. Soon, Rowling wrote a long tread defending herself and went to write, Ive ignored fake tweets attributed to me and RTed widely. Ive ignored porn tweeted at children on a thread about their art. Ive ignored death and rape threats. Im not going to ignore this. When you lie about what I believe about mental health medication and when you misrepresent the views of a trans woman for whom I feel nothing but admiration and solidarity, you cross a line.

She added, Ive written and spoken about my own mental health challenges, which include OCD, depression and anxiety. I did so recently in my essay TERF Wars. Ive taken anti-depressants in the past and they helped me. Many health professionals are concerned that young people struggling with their mental health are being shunted towards hormones and surgery when this may not be in their best interests. Many, myself included, believe we are watching a new kind of conversion therapy for young gay people, who are being set on a lifelong path of medicalisation that may result in the loss of their fertility and/or full sexual function. Adding to this, she shared links to support her tweets, giving instances. The long-term health risks of cross-sex hormones have been now been tracked over a lengthy period. These side-effects are often minimised or denied by trans activists.

Soon, people began expressing their anger. JK Rowling is now openly advocating for conversion therapy for trans kids. As a survivor of an extreme form of homebrew conversion therapy, I say *once again* without reservation that she is a danger to children, wrote one, while another said: JK Rowling comparing transitioning to conversion therapy is a great example of how conspiratorial and anti-science the TERF mindset is.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Books And Literature News, download Indian Express App.

IE Online Media Services Pvt Ltd

See the rest here:
JK Rowling faces backlash for likening transgender hormone replacement to gay conversion therapy - The Indian Express

Recommendation and review posted by Bethany Smith

Kanye West has denounced a US parenting organisation that has been promoted by his wife Kim Kardashian, as a conspiracy.

The 43-year-old rapper spoke out in his first interview since declaring his plans to run for the Presidency and hit out at Planned Parenthood.

The organisation says it provides essential health care services like STD testing and treatment, birth control, well-woman exams, cancer screening and prevention, abortion, hormone therapy and infertility services.

Kanye has denounced it as 'the devil's work' as he claims he is "following the word of the bible" despite wife Kim's support of Planned Parenthood and her pro-choice views.

Speaking to Forbes about his 2020 presidential campaign, Kanye revealed that he was running for office because he had received a message from God as the born again Christian set out some of his thoughts.

One of his main claims was that Planned Parenthood was the work of "white supremacists" which has prompted a swift response from the organisation.

Kanye said: I am pro-life because Im following the word of the bible. Planned Parenthoods have been placed inside cities by white supremacists to do the Devils work.

Planned Parenthoods Director of Black Leadership and Engagement, Nia Martin-Robinson, hit back at Kanye's remarks in a statement.

She said: "Black women are free to make our own decisions about our bodies and pregnancies, and want and deserve to have access to the best medical care available.

Any insinuation that abortion is Black genocide is offensive and infantilising.

"The real threat to Black communities safety, health, and lives stems from lack of access to quality, affordable health care, police violence and the criminalisation of reproductive health care by anti-abortion opposition.

Keeping Up With The Kardashians fans will recall that Kim was joined by her sisters Khloe and Kourtney at a Planned Parenthood clinic for a visit in 2017.

Kim publicly voiced her support at the time on Instagram, sharing a photo of them at one of the clinics, captioning it with: "My sisters and I visited Planned Parenthood recently and learned that the House of Representatives forced through a bill that strips health care coverage from millions of people and raises health care costs, including Planned Parenthood patients.

They are such an amazing place that provides so much to so many! #istandwithpp.

Do you have a story to sell? Get in touch with us at webcelebs@trinitymirror.com or call us direct 0207 29 33033.

Continue reading here:
Kanye West sparks fury saying Planned Parenthood 'carries out the devil's work' - Mirror Online

Recommendation and review posted by Bethany Smith

Ah, there it is again hunger, causing your tummy to grumble and your mind to drift away from the task in front of you. "Didn't I just have lunch an hour ago?" you might ask yourself as you make your fifth trip to peer into the fridge again. Hunger is natural and is supposed to be self-regulated; these days, everyone on talk shows and on Instagram seem to be talking about "intuitive" eating or listening to your body's needs, especially when you feel hungry. We bet you know when you've crossed a line, though, and "snacking" turns into an unintentional fourth or fifth meal. If you constantly feel hungry no matter what you're eating, it's time to think about what you're putting on the plate.

Sometimes, an unchecked increase in appetite can be explained by other health conditions or life situations (such as breast feeding), or even by medications you take. But more often, there may be other choices you're making during the day that might unintentionally add fuel to your endless appetite. Below, with the help of a holistic panel of health experts assembled by Good Housekeeping, we explore some of the reasons you may be feeling hungry all of the time and how to fix them, starting right now.

Believe it or not, sometimes our body processes thirst in the same way that it processes hangry pangs, and you could be mistaking thirst for hunger. Stefani Sassos, MS, RDN, CDN, the Good Housekeeping Institute's registered dietitian, explains that how much water you drink directly influences how "satiated" (full!) you feel during the day. "My biggest tip is not to wait until you're 'thirsty' to grab some water chances are that you're already dehydrated if you're feeling thirst or dry mouth," Sassos says, adding that most women need to consume at least 72 ounces of water each day (but that formula may depend on your size and activity level). "Set a schedule for yourself to space out your water intake throughout the day and make it a priority." Plus, upping how much water you're drinking on average may be a boon for weight loss if you're dieting or exercising, as Sassos links being properly hydrated to active metabolic rates throughout the day.

How do you know if you're actually thirsty and not truly hungry in the moment? Try drinking a glass or two of water before you decide if it's time to eat again, and wait a few minutes. "You'll be able to gauge whether you're truly hungry or just thirsty," Sassos says.

Meaning, you may be missing out on a much-needed meal (like breakfast!) when you're burning through a bunch of energy during the day or, you're mindlessly eating when you're simply bored on the couch. Comprehensive research establishing the link between hunger and physical activity is lacking, but as Sassos points out, limited research suggests that exercise may trick your body into suppressing appetite during a workout (your body temperature may have something to do with that phenomena). If you're not eating wholesome meals before or after prolonged activity cycling, running, swimming, lifting weights, as examples you may be setting yourself up for intense hunger pangs later in the day. "You need proper nutrition to help repair your muscle," Sasso says, adding that she'll actively pad her meals with nutritious picks to "complement" her workout session.

Conversely, you may be engaging in distracted or mindless eating when you're sedentary (think: on the couch, at your desk, or in the car). "If you're sedentary most of the day and not doing much, boredom can certainly entice you to eat more," Sassos says. "If you just ate and know you should feel full, but are bored and want to eat more, consider distracting yourself pick up a book, or actually get up and exercise! If I know I'm just bored and not hungry, I'll hold a plank for a minute and that craving will go away."

Fiber is that magical ingredient that makes a meal feel really filling as opposed to something that doesn't really satisfy you after you've finished eating, explains Julie Benard, M.D., a board-certified pediatric obesity medicine specialist and a pediatrician within the University of Missouri Health Care system. "A diet low in fiber can cause frequent hunger, as fiber is broken down slowly by our gastrointestinal tract, which leads to more stable blood sugar levels and therefore less feelings of hunger," she says.

You should be aiming to eat your way through 25g of fiber throughout the day, Sassos says. But you don't have to painstakingly count at first: Load up on meals that are highly fibrous, that incorporate things like avocados, beans, or most nuts as the main attraction. You should feel the results soon thereafter: "High-fiber foods may actually take longer to chew, are slower to digest, and promote satiety," Sassos says.

Dr. Benard and Sassos don't want you to believe all carbs are bad: Whole grains, fruits, and vegetables all contain naturally occurring carbohydrates, and they are definitely pillars of any healthy diet. Refined carbohydrates, however, should be enjoyed occasionally. White breads, pasta, and pastries, among many other items that are also high in saturated fats and sugar, cause a spike in insulin, a hormone that helps regulate blood sugar. "We get an initial burst of energy and satiety from these starchy and sugary treats, but then insulin causes our body to burn through that sugar quickly," Dr. Benard explains. "This leads to subsequent rapid declines in blood sugar that trigger our feelings of hunger once again."

Photo credit: Getty Images

Sugar is a carbohydrate too, and it's often the main ingredient in refined carbohydrates alongside classic desserts that you're thinking of right now. You probably are sick to death of hearing about that afternoon "sugar crash," when your blood sugar plummets after eating something very sweet, which later causes you to reach for even more food to help you get your blood sugar back up again. But did you know that repeatedly working your way through this cycle may cause lasting damage? Sugar and refined carbohydrates play into constant elevated blood sugar that can lead to insulin resistance, when your body can't use glucose from your blood for energy (a form of prediabetes), Sassos says.

"Interestingly enough, insulin shares similarities with leptin a hormone that helps to regulate appetite and weight control," she explains. "Lepin and insulin actually directly regulate each other, and in the case of insulin resistance, this will cancel out the 'appetite-control' effect and can lead to a vicious hunger cycle." Sugar is naturally found in nutritious items like fruits, but if you can identify snacks in your daily rotation that are high in added sugars or processed carbs, those are some of the first items you should cut back on.

If you're new to trying out a vegetarian or vegan diet, this could be especially true. And protein doesn't just mean red meat! It includes lean fish, poultry, and plant-based items like tofu or lentils. "A diet low in protein can also lead to frequent feelings of hunger, even though one may be consuming a higher amount of calories," Dr. Benard says.

She explains that a hormone called ghrelin is the hormone responsible for our hunger pangs at the molecular level, and is released when the stomach is empty. Our stomach is stretched in the process of eating, thus decreasing the levels of ghrelin released, but "what we're eating can determine how long our ghrelin levels stay low," Dr. Benard says. "Protein is the most effective nutrient at keeping ghrelin low for longer periods of time, especially compared to carbohydrates." Science!

Which is why you may always fall prey to a post-lunch (or dinner) snack later on. "A lot of people will tell me they're 'being good' with their nutrition up until the afternoon, where cravings hit and they just fall off the wagon," Sassos explains. "When I go to analyze their 'good' mornings, it's usually just low-calorie! Restricting yourself early in the day actually may set you up for failure as the day progresses."

There's been a lot of debate around skipping breakfast recently, and some dieters swear by restricting their meals to certain hours of the day (often referred to as intermittent fasting). Regardless of when you choose to eat your first meal of the day, it should be full of nourishing items alongside plenty of water, Sassos recommends. "Im a fan of bulking up that breakfast and lunch meal with lean protein, healthy fiber, and tons of vegetables to keep you full for hours," she says. "Eating fiber in the morning can help to control afternoon cravings, and I like to look at it as making an investment to help you have a successful day."

Feeling hungry might be a side effect of purposefully not feeding yourself because you feel that you've "lost control," says David Schlundt, PhD, an associate professor of psychology at Vanderbilt University and a member of the university's Diabetes Research and Training Center. "Food provides some temporary relief from negative emotion, but hunger is rarely the trigger for emotional eating It's a problem when people impose unrealistically strict dietary rules on themselves," he says.

For example, if you believe that you shouldn't eat breakfast because it'll make you gain weight, then you will likely feel hungry when you skip it and then break other self-imposed dietary rules. "An example might be that you believe donuts are bad, but when you're hungry and there's a donut in the break room, you pick up two when no one is looking," Schlundt explains. "This becomes a problem not because you took in calories your body was telling you to do that but because the perceived rule violation is a negative experience leading to guilt, self-blame, and abstinence violation. This is the extended loss of control that occurs as a result of your self-defined dietary violation."

This behavior can lead you to be extremely restrictive in what you eat, when you eat, or how much you eat later on, Schlundt says, all factors that can influence your appetite.

Photo credit: Mike Garten

Ah, yet another way that sleep can impact our daily lives. Not getting enough rest at night may inadvertently affect how much you're eating throughout the day, especially if you're frequently getting less than 7 hours of sleep. "Feeling sleep deprived can do a number on our will power, as we then tend to not make the best nutrition choices," Dr. Benard says, like easy ready-to-eat items containing refined carbs and sugar. "On a hormonal level, some studies also suggest that a lack of sleep may be associated with lower levels of leptin our 'feeling full' hormone and higher levels of ghrelin the hungry hormone."

These hormones may be at the heart of why sleep deprivation has been associated with excessive weight gain over a longer period, Sassos says. A landmark study published in the American Journal of Epidemiology followed 60,000 women over 16 years while recording their sleep habits and dietary functions alongside other lifestyle aspects; it noted that women who slept 5 hours or less per night had a 15% higher risk of becoming obese, and were 30% more likely to gain 30 pounds in the same time frame compared to women who slept 7 hours each night.

All to say: You should be doing everything in your power to establish better sleep hygiene, and work on creating a better-for-you bedtime routine.

"I like to categorize cravings by whether they're coming from above the neck or below the neck," Sassos explains. "Above the neck cravings are emotional, often come on suddenly, and aren't satisfied even if you do eat a full meal. They may trigger feelings of shame and guilt, and you may feel like you have no control over your food choices."

On the flip side, then, "below the neck" cravings are actually a sign of physical hunger that you shouldn't ignore, Sassos says. "These cravings build gradually, and many food options sound appealing. Once you're sensibly full, the cravings go away. Below the neck cravings aren't associated with any feelings of guilt or anger, but rather you feel satisfied or even relieved after eating that particular item or meal."

Stress has a terrible way of impacting much of our lives, including how much we eat; the flight-or-fight response associated with stress can lead to an increase in hunger later on (the Cleveland Clinic even lists hunger a side effect of stress). But more seriously, Schlundt says that a severe, sustained change in appetite is one of the main symptoms of major depressive disorder. "There are two types of people: Those who eat more when depressed, and those who lose interest in food when depressed," he adds. "Eating more when depressed may be more complicated than just increased hunger. It is probably some degree of loss of control over behavior rather than hunger alone."

If mealtimes have become an unstable part of your day and feel that it might be due to anxiety, depression, or emotional trauma, you should consider seeking out professional help. The American Psychological Association's Psychologist Locator tool can help you find a licensed therapist in your area that takes your insurance.

Underlying conditions like these can be the source of your insatiable appetite, but this is probably the least likely explanation for feeling hungry all the time. "Increased hunger can certainly be a sign of diabetes, alongside increased thirst or frequent urination," Dr. Benard says. "It also could be a sign of hyperthyroidism, which goes hand in hand with an increased heart rate, feeling jittery, or losing weight without trying There are rarely genetic changes that can lead to insatiable hunger as well."

If you feel like you've exhausted the suggestions on this list to no avail, it's time to schedule a checkup with your healthcare provider, where you can address your diet and other aspects of your hunger in depth. Your appetite may be caused by a condition that's beyond your control and could require qualified attention.

You Might Also Like

See the rest here:
Health Experts Weigh In on the Real Reason You're Always Feeling Hungry - Yahoo Canada Shine On

Recommendation and review posted by Bethany Smith

A simple test of a womans hair could tell women how many eggs they have left by judging levels of a key fertility hormone, scientists say.

US and Spanish researchers found biologically relevant levels of anti-Mllerian hormone (AMH) an indicator of ovarian reserves in womens hair samples.

AMH is a hormone produced by the cells within a womans ovaries and gives an indication of her egg reserves and subsequent fertility.

The hormone is incorporated into the matrix of hair before it reaches the surface of the skin.

Levels of AMH from the hair correlated with levels from blood samples, which is currently the most common method of measuring the hormone.

But taking AHM readings from the hair would be less invasive than a blood sample and a more appropriate representation of hormone levels, according to scientists.

Testing can be done without visiting a clinic, such as by sending a hair sample through the post, which makes this type of test cheaper and available to a broader range of women.

The role of AMH as a measure of ovarian reserve in predicting response to ovarian stimulation for IVF now seems beyond question, researchers add.

Hair is a medium that can accumulate biomarkers over several weeks, while serum is an acute matrix representing only current levels, said Sarthak Sawarkar at US health tech firm MedAnswers, who presented his research online at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology.

While hormone levels in blood can fluctuate rapidly in response to stimuli, hormone levels measured in hair would represent an accumulation over several weeks.

A measurement using a hair sample is more likely to reflect the average hormone levels in an individual.

AMH has become a key marker in the assessment of how women may respond to fertility treatment.

The hormone is produced by small cells surrounding each egg as it develops in the ovary.

Studies have not correlated AMH levels to a reliable chance of live birth, nor to forecasting the time of menopause.

However, AMH measurement has become an intrinsic marker in assessing how a patient will respond to ovarian stimulation for IVF as a normal responder, poor responder (with few eggs), or over-responder (with many eggs and a risk of ovarian hyperstimulation syndrome).

Currently, AMH is presently measured in serum taken from a blood sample drawn intravenously, but readings taken this way represent just a snapshot of a moment in time and are relatively invasive to complete.

To learn more about the potential of AMH readings taken from the hair, researchers collected hair and blood samples 152 women from whom hair were during hospital visits.

AMH was also measured in blood samples from the same subjects, as well as an ultrasound count of developing follicles in the ovary a method known as antral follicle count (AFC).

Biologically relevant AMH levels were successfully detected in the hair samples, which declined with patient age, as expected by the team.

AMH levels from hair strongly correlated with levels as determined by both serum in the blood and AFC.

The hair test was also able to detect a wide range of AMH levels within individuals from a similar age cohort, suggesting a greater accuracy than from a single blood sample.

Hormones accumulate in hair shafts over a period of months, while hormone levels in serum can change over the course of hours, they found, meaning the hair test may be a more reliable measurement.

Hormone levels are also assessed non-invasively, which reduces testing stress and offers a less expensive assay.

This study is very interesting as it suggests AMH can be reliably measured from hair samples as opposed to the standard approach of a blood test, Tim Child, medical director at Oxford Fertility, told the Times.

The AMH level in hair is more likely to be averaged-out over a time period rather than the more instant level in a blood sample.

The question is whether the hair AMH levels correlate to the ovarian response and therefore numbers of eggs collected during an IVF cycle this is not examined in this study.

If the correlation is poor then hair samples will be of no benefit.

If the correlation is as good as, or perhaps even better than with blood AMH, then this technique promises to further simplify the fertility treatment process for women and will be an exciting development.

The results have been presented by PhD student Sarthak Sawarkar, working in the laboratory of Professor Manel Lopez-Bejar in Barcelona, with collaborators from MedAnswers.

Read this article:
Simple hair test 'could tell women how many eggs they have left' - Brinkwire

Recommendation and review posted by Bethany Smith

The Global Bone Marrow Transplant Rejection Treatment Market report provides a comprehensive analysis of the major market players in the regional and global regions. The Bone Marrow Transplant Rejection Treatment market report provides an in-depth analysis of the market growth aspects, opportunities, status, size in terms of value and volume, and market segmentation along with the market revenue. The research report on global Bone Marrow Transplant Rejection Treatment market offers a detailed overview of the regional as well as local market. In addition, the report also studies market outlook and status of the global and major regions on the basis of product, application, and key market players. Furthermore, the Bone Marrow Transplant Rejection Treatment market report offers a complete analysis of the global market, and the report also comprises an extensive study of application and product type with the comprehensive regional scenario. With the objective to offer a complete market overview the Bone Marrow Transplant Rejection Treatment report includes regional competitive landscape for the number of major market service providers.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4815878

In addition, the Bone Marrow Transplant Rejection Treatment market report also provides the latest trends in the global Bone Marrow Transplant Rejection Treatment market with the help of primary as well as secondary research methodologies. On the other hand, the Bone Marrow Transplant Rejection Treatment market report also studies the market status for the forecast period. However, this will help to increase the marketing opportunities across the world as well as major market providers. Additionally, the research report on Bone Marrow Transplant Rejection Treatment market provides a broad analysis of the market which includes market overview, production, producers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of the global Bone Marrow Transplant Rejection Treatment market. In addition to this, the Bone Marrow Transplant Rejection Treatment market report also provides helpful insights for every established and innovative players across the globe.

Major companies of this report:

Bellicum Pharmaceuticals, Inc.Bio-Cancer Treatment International LimitedBiogen IncBoryung Pharmaceutical Co., Ltd.Bristol-Myers Squibb CompanyCantex Pharmaceuticals, Inc.Capricor Therapeutics, Inc.Cell Source, Inc.Cell2B S.A.CellECT Bio, Inc.Cleveland BioLabs, Inc.Compugen Ltd.Cynata Therapeutics LimitedCytodyn Inc.Dompe Farmaceutici S.p.A.Dr. Falk Pharma GmbHEscape Therapeutics, Inc.F. Hoffmann-La Roche Ltd.Fate Therapeutics, Inc.Generon (Shanghai) Corporation Ltd.Gilead Sciences, Inc.GlaxoSmithKline PlcIdera Pharmaceuticals, Inc.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2015-2025-global-bone-marrow-transplant-rejection-treatment-market-research-by-type-end-use-and-region-covid-19-version

This research report extensively studies the most influencing driving factors and also contains the information about restraining factors that are hampering the growth of the global Bone Marrow Transplant Rejection Treatment market. The report also offers the detailed information about the market share and market segmentation on the basis of major segments of the market. The global Bone Marrow Transplant Rejection Treatment market report also contains the manufacturers data which may comprise price, shipment, revenue, interview record, gross profit, and business distribution which help the customers to know about the global Bone Marrow Transplant Rejection Treatment market competitive landscape better.

Segmentation by Type:

AzathioprineAdrenocorticotropic HormoneCyclophosphamideCyclosporine AOthers

Segmentation by Application:

HospitalClinicOthers

The Bone Marrow Transplant Rejection Treatment market report offers a comprehensive study of the technological growth outlook over time to know the market growth rates. This report also gives a better understanding about the substantial product components as well as their future. The Bone Marrow Transplant Rejection Treatment market report evaluates the Bone Marrow Transplant Rejection Treatment market, major issues, production procedures, and their solutions to meet the consumer requirements.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4815878

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Originally posted here:
Global Bone Marrow Transplant Rejection Treatment Market Report 2020, Size, Share, Business Plan, Growth Opportunities, Top Players, Application,...

Recommendation and review posted by Bethany Smith

There is no greater feeling than that of being a parent. This is what most parents say when you ask them how they feel about being parents, and we fully agree with them. Because the joy of bringing life into this world is completely overwhelming. The joy of becoming parents, for couples suffering from infertility problems, is above everything in this world. For us (me and my wife) to undergo this experience was a very long journey on a tough road, full of pain, stress, worry, and tensions.

After we got married in Sept 2013, my wife was suffering from some infertility problem so we couldnt conceive naturally. It is after the 10th month of our marriage the most difficult phase of our life started when people in our neighborhood, friends and relatives stared, asking queries, especially womenfolk; as it is common in our culture people start asking Kehn Chusa, meaning if they have conceived. You hear this talk just after only a few months of marriage. The infertile couples like us face so many problems, a mental harassment. Same is the case with us. We got treatment from leading gynaecologists and infertility specialists of the valley, who prescribed every kind of test, scan, hormone therapy, laparoscopy, HSG, and loads of medicines. One day we used to visit clinic and the next day to some peer baba. On the one hand doctors looted us in lacks, on the other hand peer babas in thousands. This took a heavy toll on our bodies. It consumed us physically, mentally and psychologically. We lost our precious assets, health deteriorated, money wasted, and our valuable time consumed in it. But all in vain.

God is great. We never lost hope and our prayers were accepted. When, on one day I came across an advertisement in a newspaper about Dr. Manika Khanna from Delhi, a leading IVF Specialist. We visited for appointment to Karan Nagar, Srinagar, and after consultations we decided to accept her advice to visit Delhi for IVF Treatment. That visit changed our life for good. In our first attempt we conceived (Gaudium IVF Hospital Delhi). Manika Madam came like an angel in our life. She and her dedicated team including names like Dr. Meetu, Dr. Nikita, staff nurses like Minni sister etc. work very hard to bring happiness in childless families. I am thankful to almighty Allah who sent an angel in the form of Manika madam and her team Gaudium, for providing us life changing experience. At the same time I am thankful to dear Ishfaq Shaheen who belongs to Srinagar branch of Gaudium who guided me and all such couples like us throughout this successful journey.

At last I would like to advice all such couples, dont waste your hard earned money and your precious time. Consult some authentic specialist, and then leave it to God.

More here:
Infertility, and the stress thereof - Greater Kashmir

Recommendation and review posted by Bethany Smith

Endometriosis Therapies Market 2020: Inclusive Insight

Los Angeles, United States, July 2020: The Endometriosis Therapies on the Move market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the market. Report Hives latest publication, Titled [Endometriosis Therapies on the Move Market Research Report 2020], offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the Endometriosis Therapies on the Move market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

The research study includes the latest updates about the COVID-19 impact on the Endometriosis Therapies on the Move sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy. Key players in this market are AbbVie, Eli Lilly, AstraZeneca, Bayer, Astellas Pharma, Meditrina Pharmaceuticals, Pfizer, Neurocrine Biosciences, Takeda Pharmaceutical

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Endometriosis Therapies Market:

There are 10 Chapters to deeply display the Endometriosis Therapies market:

Chapter 1, is executive summary of Endometriosis Therapies Market; Chapter 2, is definition and segment of Endometriosis Therapies; Chapter 3, to show info and data comparison of Endometriosis Therapies Players; Chapter 4, to explain the industry chain of Endometriosis Therapies; Chapter 5, to show comparison of regions and courtiers(or sub-regions); Chapter 6, to show competition and trade situation of Endometriosis Therapies Market; Chapter 7, to show comparison of applications; Chapter 8, to show comparison of types; Chapter 9, to show investment of Endometriosis Therapies Market; Chapter 10, to forecast Endometriosis Therapies market in the next years.

Global Endometriosis Therapies Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of Report Hive Research the Endometriosis Therapies market has witnessed an unprecedented growth till 2020. The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

COVID-19 Impact on Endometriosis Therapies Market

This study specially analyses the impact of Covid-19 outbreak on the Endometriosis Therapies Market, covering the supply chain analysis, impact assessment to the Endometriosis Therapies Market size growth rate in several scenarios, and the measures to be undertaken by Endometriosis Therapies Market companies in response to the COVID-19 epidemic.

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the Endometriosis Therapies Market industry report; it identifies direct or indirect competitors in the market.

Key parameters which define the Competitive Landscape of the Endometriosis Therapies Market:

Revenue and Market Share by Player Production and Share by Player Average Price by Player Base Distribution, Sales Area and Product Type by Player Concentration Rate Mergers & Acquisitions, Expansion Manufacturing Base

While segmentation has been provided to list down various facets of the Endometriosis Therapies market, analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. Summarization of various aspects consisted of the report has also been encompassed.

Analysis of Global Endometriosis Therapies Market: By Type

Hormonal Contraceptives, Gonadotropin-releasing Hormone (Gn-RH) Agonists , Progestin Therapy, Aromatase Inhibitors

Analysis of Global Endometriosis Therapies Market: By Application

Hospital, Clinic, Other

Endometriosis Therapies Market: Regional analysis includes:

North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, etc.) Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Our exploration specialists acutely ascertain the significant aspects of the global Endometriosis Therapies market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Endometriosis Therapies market situation. In this Endometriosis Therapies report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Endometriosis Therapies report comprises of primary and secondary data which is exemplified in the form of pie outlines, Endometriosis Therapies tables, analytical figures, and reference diagrams. The Endometriosis Therapies report is presented in an efficient way that involves basic dialect, basic Endometriosis Therapies outline, agreements, and certain facts as per solace and comprehension.

>>> To get Incredible Discounts on this Premium Report, Click Here @ https://www.reporthive.com/2303357/check_discount

Some of the Major Highlights of TOC covers:

1 Study Coverage1.1 Endometriosis Therapies Product Introduction1.2 Market Segments1.3 Key Endometriosis Therapies Manufacturers Covered: Ranking by Revenue1.4 Market 21.4.1 Global Endometriosis Therapies Market Size Growth Rate 21.4.2 Hormonal Contraceptives, Gonadotropin-releasing Hormone (Gn-RH) Agonists , Progestin Therapy, Aromatase Inhibitors1.5 Market 31.5.1 Global Endometriosis Therapies Market Size Growth Rate 31.5.2 Hospital, Clinic, Other1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Endometriosis Therapies Market Size, Estimates and Forecasts2.1.1 Global Endometriosis Therapies Revenue 2015-20262.1.2 Global Endometriosis Therapies Sales 2015-20262.2 Global Endometriosis Therapies, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Endometriosis Therapies Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Endometriosis Therapies Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Endometriosis Therapies Competitor Landscape by Players3.1 Endometriosis Therapies Sales by Manufacturers3.1.1 Endometriosis Therapies Sales by Manufacturers (2015-2020)3.1.2 Endometriosis Therapies Sales Market Share by Manufacturers (2015-2020)3.2 Endometriosis Therapies Revenue by Manufacturers3.2.1 Endometriosis Therapies Revenue by Manufacturers (2015-2020)3.2.2 Endometriosis Therapies Revenue Share by Manufacturers (2015-2020)3.2.3 Global Endometriosis Therapies Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Endometriosis Therapies Revenue in 20193.2.5 Global Endometriosis Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Endometriosis Therapies Price by Manufacturers3.4 Endometriosis Therapies Manufacturing Base Distribution, Product Types3.4.1 Endometriosis Therapies Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Endometriosis Therapies Product Type3.4.3 Date of International Manufacturers Enter into Endometriosis Therapies Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size 2 (2015-2026)4.1 Global Endometriosis Therapies Market Size 2 (2015-2020)4.1.1 Global Endometriosis Therapies Sales 2 (2015-2020)4.1.2 Global Endometriosis Therapies Revenue 2 (2015-2020)4.1.3 Endometriosis Therapies Average Selling Price (ASP) 2 (2015-2026)4.2 Global Endometriosis Therapies Market Size Forecast 2 (2021-2026)4.2.1 Global Endometriosis Therapies Sales Forecast 2 (2021-2026)4.2.2 Global Endometriosis Therapies Revenue Forecast 2 (2021-2026)4.2.3 Endometriosis Therapies Average Selling Price (ASP) Forecast 2 (2021-2026)4.3 Global Endometriosis Therapies Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size 3 (2015-2026)5.1 Global Endometriosis Therapies Market Size 3 (2015-2020)5.1.1 Global Endometriosis Therapies Sales 3 (2015-2020)5.1.2 Global Endometriosis Therapies Revenue 3 (2015-2020)5.1.3 Endometriosis Therapies Price 3 (2015-2020)5.2 Endometriosis Therapies Market Size Forecast 3 (2021-2026)5.2.1 Global Endometriosis Therapies Sales Forecast 3 (2021-2026)5.2.2 Global Endometriosis Therapies Revenue Forecast 3 (2021-2026)5.2.3 Global Endometriosis Therapies Price Forecast 3 (2021-2026)

6 North America6.1 North America Endometriosis Therapies by Country6.1.1 North America Endometriosis Therapies Sales by Country6.1.2 North America Endometriosis Therapies Revenue by Country6.1.3 United States6.1.4 Canada6.1.5 Mexico6.2 North America Endometriosis Therapies Market Facts & Figures 26.3 North America Endometriosis Therapies Market Facts & Figures 3

7 Europe7.1 Europe Endometriosis Therapies by Country7.1.1 Europe Endometriosis Therapies Sales by Country7.1.2 Europe Endometriosis Therapies Revenue by Country7.1.3 Germany7.1.4 France7.1.5 UK7.1.6 Italy7.1.7 Russia7.2 Europe Endometriosis Therapies Market Facts & Figures 27.3 Europe Endometriosis Therapies Market Facts & Figures 3

8 Asia Pacific8.1 Asia Pacific Endometriosis Therapies by Region8.1.1 Asia Pacific Endometriosis Therapies Sales by Region8.1.2 Asia Pacific Endometriosis Therapies Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Indonesia8.1.9 Thailand8.1.10 Malaysia8.1.11 Philippines8.1.12 Vietnam8.2 Asia Pacific Endometriosis Therapies Market Facts & Figures 28.3 Asia Pacific Endometriosis Therapies Market Facts & Figures 3

9 Latin America9.1 Latin America Endometriosis Therapies by Country9.1.1 Latin America Endometriosis Therapies Sales by Country9.1.2 Latin America Endometriosis Therapies Revenue by Country9.1.3 Brazil9.2 Central & South America Endometriosis Therapies Market Facts & Figures 29.3 Central & South America Endometriosis Therapies Market Facts & Figures 3

10 Middle East and Africa10.1 Middle East and Africa Endometriosis Therapies by Country10.1.1 Middle East and Africa Endometriosis Therapies Sales by Country10.1.2 Middle East and Africa Endometriosis Therapies Revenue by Country10.1.3 Turkey10.1.4 GCC Countries10.1.5 Egypt10.1.6 South Africa10.2 Middle East and Africa Endometriosis Therapies Market Facts & Figures 210.3 Middle East and Africa Endometriosis Therapies Market Facts & Figures 3

11 Company Profiles11.1 Company111.1.1 Company1 Corporation Information11.1.2 Company1 Description and Business Overview11.1.3 Company1 Sales, Revenue and Gross Margin (2015-2020)11.1.4 Company1 Endometriosis Therapies Products Offered11.1.5 Company1 Related Developments11.2 Company211.2.1 Company2 Corporation Information11.2.2 Company2 Description and Business Overview11.2.3 Company2 Sales, Revenue and Gross Margin (2015-2020)11.2.4 Company2 Endometriosis Therapies Products Offered11.2.5 Company2 Related Developments11.3 Company311.3.1 Company3 Corporation Information11.3.2 Company3 Description and Business Overview11.3.3 Company3 Sales, Revenue and Gross Margin (2015-2020)11.3.4 Company3 Endometriosis Therapies Products Offered11.3.5 Company3 Related Developments11.4 Company411.4.1 Company4 Corporation Information11.4.2 Company4 Description and Business Overview11.4.3 Company4 Sales, Revenue and Gross Margin (2015-2020)11.4.4 Company4 Endometriosis Therapies Products Offered11.4.5 Company4 Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)12.1 Endometriosis Therapies Market Estimates and Projections by Region12.1.1 Global Endometriosis Therapies Sales Forecast by Regions 2021-202612.1.2 Global Endometriosis Therapies Revenue Forecast by Regions 2021-202612.2 North America Endometriosis Therapies Market Size Forecast (2021-2026)12.2.1 North America: Endometriosis Therapies Sales Forecast (2021-2026)12.2.2 North America: Endometriosis Therapies Revenue Forecast (2021-2026)12.2.3 North America: Endometriosis Therapies Market Size Forecast by Country (2021-2026)12.3 Europe Endometriosis Therapies Market Size Forecast (2021-2026)12.3.1 Europe: Endometriosis Therapies Sales Forecast (2021-2026)12.3.2 Europe: Endometriosis Therapies Revenue Forecast (2021-2026)12.3.3 Europe: Endometriosis Therapies Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Endometriosis Therapies Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Endometriosis Therapies Sales Forecast (2021-2026)12.4.2 Asia Pacific: Endometriosis Therapies Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Endometriosis Therapies Market Size Forecast by Region (2021-2026)12.5 Latin America Endometriosis Therapies Market Size Forecast (2021-2026)12.5.1 Latin America: Endometriosis Therapies Sales Forecast (2021-2026)12.5.2 Latin America: Endometriosis Therapies Revenue Forecast (2021-2026)12.5.3 Latin America: Endometriosis Therapies Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Endometriosis Therapies Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Endometriosis Therapies Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Endometriosis Therapies Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Endometriosis Therapies Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Endometriosis Therapies Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Endometriosis Therapies Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

>>> Make an enquiry before buying this report @ https://www.reporthive.com/2303357/enquiry_before_purchase

Why Report Hive Research:

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc.

Contact Us:

Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: https://www.reporthive.comEmail: [emailprotected]Phone: +1 312-604-7084

Read more:
COVID-19 Impact on Endometriosis Therapies Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2026 - Owned

Recommendation and review posted by Bethany Smith

The FDA has put a phase 1 trial of Cellectis off-the-shelf CAR-T therapy UCARTCS1A on clinical hold after learning of a death in the study. Cellectis said the multiple myeloma patient suffered a cardiac arrest after receiving the highest dose of the anti-CS1 allogeneic CAR-T.

Before joining the Cellectis trial, the patient underwent multiple prior lines of treatment, including with autologous CAR-T cells, without success. In the Cellectis trial, the patient was the first person to receive the higher, 3 million cells per kilogram dose of UCARTCS1A. The patient experienced cytokine release syndrome of undisclosed severity and died of a cardiac arrest 25 days after treatment.

The FDA has placed the trial on clinical hold while Cellectis evaluates the case. According to Cellectis, plans were already afoot to expand the lower, 1 million cells per kilogram dose cohort before the patient death. Preliminary data suggest 1 million cells per kilogram may be the phase 2 dose.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

There are signs the lower dose also has some safety issues. Analysts at Jefferies think investigators gave one or more of the three low-dose patients rituximab to activate the CAR-T safety switch. Work is underway to update the phase 1 protocol to mitigate the potential risks posed by UCARTCS1A.

The modifications may include increased monitoring of parameters related to cytokines. The Jefferies analysts think Cellectis should exclude patients previously treated with anti-BCMA CAR-Ts, such as Johnson & Johnsons JNJ-4528, due to risks related to back-to-back rounds of lymphodepletion, but note that management at the biotech think it is important to enroll that pre-treated population.

In a follow-up note, the analysts identified the use of cyclophosphamide, a chemotherapy drug, in the lymphodepletion regimen as a potential cause of the cardiac arrest. The argument is based on a 2017 paper that describes the case of a patient who died of acute heart failure after receiving a high dose of cyclophosphamide as part of an autologous stem cell transplantation treatment.

Many patients receive cyclophosphamide without suffering cardiac complications, but the analysts see reasons to think the subject enrolled in the Cellectis trial may have been at higher risk. Notably, prior exposure may increase risk, according to the analysts, suggesting the patients previous round of lymphodepletion may have been a factor.

Even if cyclophosphamide is at the heart of the problem, the analysts still think the UCARTCS1A dose is a contributing factor. With patients in the low-dose cohort also experiencing adverse events, the analysts see dosing at below 1 million cells per kilogram as one possible outcome of the situation.

Shares in Cellectis fell 13% in after-hours trading following news of the clinical hold. The value of Allogene Therapeutics, which licensed CAR-T assets that originated at Cellectis, held steady, likely reflecting a belief that the safety issue is limited to UCARTCS1A.

The Jefferies analysts see little or no read-through to other allogeneic programs, noting that the UCARTCS1A trial started at a higher dose than Cellectis two other clinical programs and that Allogene is testing several lymphodepletion regimens. The FDA placed a clinical trial of another Cellectis CAR-T, UCART123, on hold in 2017 after a patient died, but cleared it to resume months later.

Originally posted here:
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold - FierceBiotech

Recommendation and review posted by Bethany Smith

Embryonic stem cells. The ethical issues associated with stem cell research could be resolved through the use of induced pluripotent stem cells, which are derived from fully committed and differentiated cells of the adult body

The almost miraculous benefits that stem cells may one day deliver have long been speculated on. Capable of becoming different types of cells, they offer huge promise in terms of transplant and regenerative medicine. It is, however, also a medical field that urges caution one that must constantly battle exaggeration. If stem cells do in fact hold the potential to reverse the ageing process, for example, then such breakthroughs remain many years away.

Recently, though, the field has had cause for excitement. In 2006, Japanese researcher Shinya Yamanaka discovered that mature cells could be reprogrammed to become pluripotent, meaning they can give rise to any cell type of the body. In 2012, the discovery of these induced pluripotent stem cells (iPSCs) saw Yamanaka and British biologist John Gurdon awarded the Nobel Prize in Physiology or Medicine. Since then, there has been much talk regarding the potential iPSCs possess, not only for the world of medicine, but for society more generally, too.

A big stepHistorically, one of the major hurdles preventing further research into stem cells has been an ethical one. Until the discovery of iPSCs, embryonic stem cells (ESCs) represented the predominant area of research, with cells being taken from preimplantation human embryos. This process, however, involves the destruction of the embryo and, therefore, prevents the development of human life. Due to differences in opinion over when life is said to begin during embryonic development, stem cell researchers face an ethical quandary.

The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals

With iPSCs, though, no such dilemmas exist. IPSCs are almost identical to ESCs but are derived from fully committed and differentiated cells of the adult body, such as a skin cell. Like ESCs, iPSCs are pluripotent and, as they are stem cells, can self-renew and differentiate, remaining indefinitely propagated and retaining the ability to give rise to any human cell type over time.

One important distinction to make is that both ESCs and iPSCs do not exist in nature, Vittorio Sebastiano, Assistant Professor (Research) of Obstetrics and Gynaecology (Reproductive and Stem Cell Biology) at Stanford Universitys Institute for Stem Cell Biology and Regenerative Medicine, told The New Economy. They are both beautiful laboratory artefacts. This means that at any stage of development, you cannot find ESCs or iPSCs in the developing embryo, foetus or even in the postnatal or adult body. Both ESCs and iPSCs can only be established and propagated in the test tube.

The reason neither ESCs nor iPSCs can be found in the body is that they harbour the potential to be very dangerous. As Sebastiano explained, these cells could spontaneously differentiate into tumorigenic masses because of their intrinsic ability to give rise to any cell type of the body. Over many years of research, scientists have learned how to isolate parts of the embryo (in the case of ESCs) and apply certain culture conditions that can lock cells in their proliferative and stem conditions. The same is true for iPSCs.

To create iPSCs, scientists take adult cells and exogenously provide a cocktail of embryonic factors, known as Yamanaka factors, for a period of two to three weeks. If the expression of such factors is sustained for long enough, they can reset the programme of the adult cells and establish an embryonic-like programme.

Turning back the clockThere is already a significant body of research dedicated to how stem cells can be used to treat disease. For example, mesenchymal stem cells (usually taken from adult bone marrow) have been deployed to treat bone fractures or as treatments for autoimmune diseases. It is hoped that iPSCs could hold the key for many more treatments.

Global stem cell market:25.5%Expected compound annual growth rate (2018-24)$467bnExpected market value (2024)

IPSCs are currently utilised to model diseases in vitro for drug screening and to develop therapies that one day will be implemented in people, Sebastiano explained. Given their ability to differentiate into any cell type, iPSCs can be used to differentiate into, for example, neurons or cardiac cells, and study specific diseases. In addition, once differentiated they can be used to test drugs on the relevant cell type. Some groups and companies are developing platforms for cell therapy, and I am personally involved in two projects that will soon reach the clinical stage.

Perhaps the most exciting prospects draw on iPSCs regenerative properties. Over time, cells age for a variety of reasons namely, increased oxidative stress, inflammation and exposure to pollutants or sunlight, among others. All these inputs lead to an accumulation of epigenetic mistakes those that relate to gene expression rather than an alteration of the genetic code itself in the cells, which, over time, results in the aberrant expression of genes, dysfunctionality at different levels, reduced mitochondrial activity, senescence and more besides. Although the epigenetic changes that occur with time may not be the primary cause of ageing, the epigenetic landscape ultimately affects and controls cell functionality.

What we have shown is that, if instead of being expressed for two weeks we express the reprogramming factors for a very short time, then we see that the cells rejuvenate without changing their identity, Sebastiano said. In other words, if you take a skin cell and express the reprogramming genes for two to four days, what you get is a younger skin cell.

By reprogramming a cell into an iPSC, you end up with an embryonic-like cell the reprogramming erases any epigenetic errors. If expressed long enough, it erases the epigenetic information of cell identity, leaving embryonic-like cells that are also young.

Slow and steadyAs with any scientific advancement, financial matters are key. According to Market Research Engine, the global stem cell market is expected to grow at a compound annual growth rate of 25.5 percent between 2018 and 2024, eventually reaching a market value of $467bn. The emergence of iPSCs has played a significant role in shaping these predictions, with major bioscience players, such as Australias Mesoblast and the US Celgene, working on treatments involving this particular type of stem cell.

The business potential around stem cell research is huge, Sebastiano told The New Economy. [Particularly] when it comes to developing cell banks for which we have detailed genetic information and, for example, studying how different drugs are toxic or not on certain genetic backgrounds, or when specific susceptibility mutations are present.

Unfortunately, even as the business cases for iPSC treatments increase, a certain degree of caution must be maintained. The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals. There have been numerous reports of complications emerging, including the formation of a tumour following experimental stem cell treatment in one particular patient, as recorded in the Canadian Medical Association Journal last year. Such failures risk setting the field back years.

The challenge for researchers now will be one of balance. The potential of iPSCs is huge both in terms of medical progress and business development but can easily be undermined by misuse. Medical advancements, particularly ones as profound as those associated with iPSCs, simply cannot be rushed.

The rest is here:
Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? - The New Economy

Recommendation and review posted by Bethany Smith

Stem cells have been holding great promise for regenerative medicine for ages. In the last decade, many studies have revealed this form of cell, which in Spanish is calledmother cell due to its ability to contribute to various different cell types, may be applied in regenerative medicine to diseases such as muscle and nervous system disorders, among others.

Scientists and stem cell leaders Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea.

However, one of the key constraints in the application of these herbal remedies is the caliber of the stem cells that may be made in the lab, which impedes their use for curative purposes.

Currently, a team in the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), headed by researcher Marcos Malumbres, has recently developed a fresh, easy and fast technology that enhances in vitro and in vivo the possibility of stem cells to differentiate into adult cells. The study results will be released this week in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have.The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types.Mara Salazar-Roa, Study First Author and Researcher, Centro Nacional de Investigaciones Oncolgicas

Roa is likewise the co-corresponding author of this analysis.

Within this study, the researchers identified an RNA sequence, called microRNA 203, that can be found at the earliest embryonic stages before the embryo implants in the uterus and when stem cells have their highest ability to generate all the different cells.When they added this molecule to stem cells from the laboratory, they discovered that the cells ability to convert into other cell types improved appreciably.

To corroborate them, they used stem cells of both human and murine origin, and of genetically altered mice. The results were so spectacular, both in mouse cells and in human cells

Application of the microRNA for just 5 days boosts the potential of stem cells in most situations we tested and improves their ability to become other specialised cells, even months after being connected with the microRNA. Says Salazar-Roa.

According to the research, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the doorway to a better generation of different cell types essential for the cure of degenerative disorders.

Malumbres, mind of the CNIO Cell and Cancer Division Group, states:To deliver this asset to the clinic, cooperation with labs or companies that are looking to exploit that technology is now essential in each particular case.

In this circumstance, Salazar-Roa recently participated, in close collaboration with all the CNIOs Innovation group, in prestigious creation programs like IDEA2 International of the Massachusetts Institute of Technology (MIT) and also CaixaImpulse of thisLa Caixa Foundation, where they also obtained funding to start the maturation of the technology.

See the article here:
New technology May Raise the quality of stem cells Found in regenerative medicine - Microbioz India

Recommendation and review posted by Bethany Smith

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C). Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within five days of referral under the EAP.

The protocol was filed with the United States Food and Drug Administration (FDA) and provides physicians with access to remestemcel-L for an intermediate-size patient population1 under Mesoblast’s existing Investigational New Drug (IND) application. According to the FDA, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

MIS-C is a life-threatening complication of COVID-19 in otherwise healthy children and adolescents that includes massive simultaneous inflammation of multiple critical organs and their vasculature. In approximately 50% of cases this inflammation is associated with significant cardiovascular complications that directly involve heart muscle and may result in decreased cardiac function. In addition, the virus can result in dilation of coronary arteries with unknown future consequences. Recent articles from Europe and the United States have described this disease in detail.2-5

Mesoblast Chief Medical Officer Dr Fred Grossman said: The extensive body of safety and efficacy data generated to date using remestemcel-L in children with graft versus host disease suggest that our cellular therapy could provide a clinically important therapeutic benefit in MIS-C patients, especially if the heart is involved as a target organ for inflammation. Use of remestemcel-L in children with COVID-19 builds on and extends the potential application of this cell therapy in COVID-19 cytokine storm beyond the most severe adults with acute respiratory distress syndrome.”

Remestemcel-L Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor and is administered in a series of intravenous infusions. Remestemcel-L is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

1.www.clinicaltrials.gov; NCT04456439 2.Lancet2020; May 7. DOI: https://doi.org/10.1016/S0140-6736(20)31094-1 3.Lancet. 2020; (May 13) https://doi.org/10.1016/S0140-6736(20)31103-X 4.https://www.nejm.org/doi/full/10.1056/NEJMoa2021756 5.https://www.nejm.org/doi/full/10.1056/NEJMoa2021680

About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast’s Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward- looking statements include, but are not limited to, statements about: the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

See the original post here:
Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19...

Recommendation and review posted by Bethany Smith

New York, July 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05930381/?utm_source=GNW

Product Type:Kits, Consumables, and Services Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques Oncology Genetic Testing: Breast, Colorectal,Prostate, Lung, Melanoma Cardiology Genetic Testing: Cardiomyopathy,Aortopathy, Arrythmia Neurology Genetic Testing: Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening

Regional Segmentation North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Russia, Netherlands Asia-Pacific Japan, China, India, Australia, Singapore Latin America Brazil, Mexico Rest-of-the-World Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Cross Segmentation North America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Europe Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Latin America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Rest-of-the-World Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing

Growth Drivers Rising Prevalence of Genetic Disorders Increasing Prevalence of Various Types of Cancer, Globally Increasing Research Funding in the Field of Genomics

Market Challenges Expensive Sequencing Procedures and Their Applications in Medical Treatments High Capital Requirement Hampering the Expansion of Global Reach Stringent Regulatory Standards

Market Opportunities Technological Advancements for Exome Sequencing Rise of Direct-to-Consumer (DTC) Testing Services Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Companies ProfiledAgilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report: What are the possible long-term and short-term impacts of hereditary genetic testing on the human health continuum? What are the major market drivers, challenges, and opportunities in the hereditary genetic testing? What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in the developed and developing regions for the global hereditary genetic testing market? How are service-based companies impacting the growth of the global hereditary genetic testing industry and further shaping up future trends? How each segment of the market is expected to grow during the forecast period from 2020 to 2030? Who are the leading players with significant offerings to the global hereditary genetic testing market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future, and why? What are the needs that are yet to be met by the global hereditary genetic testing market with respect to the application area? What are the dynamics of various application areas and countries are impacting the global hereditary genetic testing market? What are the new market opportunities of various technologies influencing the growth of the global hereditary genetic testing market?

Market OverviewThe hereditary genetic testing has grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends.The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace.

However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth.The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry.

Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany France Italy U.K. Spain Russia Netherlands Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-World (RoW)Read the full report: https://www.reportlinker.com/p05930381/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post here:
Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),...

Recommendation and review posted by Bethany Smith

A new intelligence report Pre-Pregnancy Genetic Testing Market has been recently Added into Global Market Research collection of top-line market research reports. Global Pre-Pregnancy Genetic Testing Market report is a meticulous comprehensive analysis of this market that provides access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual advice sourced from authentic industry pros and extensive main industry research, the report provides insights about the historical growth pattern of Pre-Pregnancy Genetic Testing Market and current market situation. It then provides short- and long-term market development projections.

Projections are purely based on the detailed analysis of key Market dynamics that are expected to influence Pre-Pregnancy Genetic Testing Market performance and their intensity of impacting market growth within the span of assessment period.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-1458

In addition to evaluation of dynamics, the report provides In-depth examination of key business trends that are expected to act more prominently in global Pre-Pregnancy Genetic Testing Market. The study also provides valued information about the present and upcoming growth opportunities in Pre-Pregnancy Genetic Testing Market the important players and new market entrants can capitalize on.

Competitive companies And manufacturers in global market

Key Players

Some of the key market players for genetic testing market are Sequenom Laboratories, Illumina, Inc, Natera, Inc, Ariosa Diagnostics, Inc, BGI Health, Natera and LifeCodexx.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

Asia Pacific (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-1458

Opportunity assessment Provided in the Pre-Pregnancy Genetic Testing Market report Is important concerning understanding the profitable regions of investment, which are the technical insights for major market players, suppliers, vendors, and other stakeholders in Pre-Pregnancy Genetic Testing Market.

In-depth global Pre-Pregnancy Genetic Testing Market taxonomy presented in this Report offers detailed insights about each of the market sections and their sub-segments, which are categorized based on par various parameters. An exhaustive regional evaluation of global Pre-Pregnancy Genetic Testing Market divides international market landscape into essential geographies.

Regional outlook and country-wise evaluation of Pre-Pregnancy Genetic Testing Market Allows for the evaluation of multi-faceted performance of market in all the crucial markets. This advice plans to provide a wider scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Pre-Pregnancy Genetic Testing Market Report-

Taxonomy and geographical analysis of the international Pre-Pregnancy Genetic Testing Market empowers readers to spot profits in present chances and catch upcoming growth opportunities even until they approach the market location. The analysis given in report is only intended to unroll the economic, societal, regulatory and political scenarios of the marketplace specific to each area and country, which might help prospective market entrants in Pre-Pregnancy Genetic Testing Market landscape to comprehend the nitty-gritty of target market regions and invent their strategies accordingly.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-1458

Major TOC Covered In this Report are:

Excerpt from:
Pre-Pregnancy Genetic Testing Expected to Witness a Fast-paced Growth Over the Forecast Period 2016 2026 Bulletin Line - Bulletin Line

Recommendation and review posted by Bethany Smith

WASHINGTON, July 7, 2020 /PRNewswire/ --A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners has published a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially lifesaving testing options available for both new cancer diagnoses and progression or recurrence of disease.

Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants). Analysis by The Consistent Testing Terminology Working Group (Working Group) indicates that language disparity is a primary obstacle to patient communication with providers about testing for their specific cancer type. Further, development of consistent language can increase patient understanding and communication, facilitate shared decision making, support value-based care, and assure concordance in policy development.

The Working Group is a consortium of 20 cancer patient advocacy groups representing solid tumor and hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostic companies and testing laboratories. Over the course of many years, multiple activities, led by numerous individual patient advocacy organizations and professional societies, have developed the groundwork for this effort. The Working Group has launched a multi-faceted dissemination and communications effort to ensure that its recommendations and supporting materials are widely available among all key stakeholders within the cancer ecosystem, including providers, patient advocacy organizations, guidelines agencies, payers, and policymakers.

In developing its recommendations, the Working Group, first convened in 2019 by LUNGevity Foundation, identified 33 terms related to biomarker, genetic, and genomic testing that were being used in patient education and clinical care within the different cancer communities. In many cases, multiple terms were used to describe the same test. Various testing modalities, the source of testing samples, and the multiplicity of gene mutations currently identifiable by testing were contributing factors in this often-confusing overlap.

In the final analysis, three umbrella descriptor terms emerged as recommendations from the Working Group's milestone exploration: "Biomarker testing"was selected as the preferred term for tests that identify characteristics, targetable findings, or other test results originating from malignant tissue and blood; "genetic testing for an inherited mutation" and "genetic testing for inherited cancer risk" were selected as consensus terms for tests used to identify germline (inherited) mutations.

"Far too many patients across all cancer types are still missing out on essential tests for biomarkers and inherited mutations indicating cancer risk," said Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics at Baylor Sammons Cancer Center and Staff Pathologist at Baylor University Medical Center. "With rates of biomarker testing and genetic testing for an inherited mutation at sub-optimal levels for numerous patient populations, patients are not benefiting from biomarker-directed care or not learning about their inherited cancer risk. Confusion around testing terms is a driving factor in this undertesting and ultimately has a detrimental impact on patient care."

Adds Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity Foundation, "When someone is diagnosed with cancer, they're swept into a whirlwind of bewildering words and complex, pressing decisions. Our Working Group's goal is to help calm that storm of confusion with clear and consistent language that facilitates communication and medical decision-making. A unified voice and message from providers, industry, and the patient advocacy community about testing is absolutely vital to optimal cancer care."

An abstract on the Working Group's recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library.

The White Paper can be viewed in its entirety atwww.CommonCancerTestingTerminology.org.

Working Groupparticipating organizations include:

Patient Advocacy: CancerCare; Cancer Support Community;The CholangiocarcinomaFoundation;Clearity Foundation; Colorectal Cancer Alliance; Fight CRC; FORCE(Facing Our Risk of Cancer Empowered); International Cancer Advocacy Network; Leukemia & Lymphoma Society; The Life Raft Group; Lymphoma Research Foundation; Living Beyond Breast Cancer; Lung Cancer Action Network (LungCan); LUNGevity Foundation; National Lung Cancer Roundtable(American Cancer Society); PanCAN; Personalized Medicine Coalition; Prostate Cancer Foundation; Ovarian Cancer Research Alliance (OCRA); Sharsheret(The Jewish Breast & Ovarian Cancer Community);and Susan G. Komen.

Professional Societies: Association of Community Cancer Centers(ACCC);Association for Molecular Pathology(AMP); and National Society of Genetic Counselors(NSGC).

Industry Partners: Abbvie; Amgen;AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eli Lilly and Company; Foundation Medicine; Genentech;GlaxoSmithKline (GSK); Novartis; Myriad Women's Health; NeoGenomics; Pfizer; Personal Genome Diagnostics (PGDx); andThermo Fisher Scientific.

About LUNGevity Foundation

LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the diseasewhile promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivorsand those who help them live better and longer lives.

Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our visiona world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

About Lung Cancer in the US

Please visit http://www.LUNGevity.orgto learn more.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pan-cancer-consortium-moves-to-clarify-and-promote-consistent-use-of-common-terms-for-biomarker-and-germline-genetic-testing-301088874.html

SOURCE LUNGevity Foundation

Read the original post:
Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing - BioSpace

Recommendation and review posted by Bethany Smith

Submitted by Genetic Support Foundation

For those who have received a positive result after genetic testing for pathogenic variants that significantly increase cancer risk, a new resource is available for connecting with others who are in a similar situation.

Positive Results is a new Facebook group for support and resources around hereditary cancer risk. The group was formed by Genetic Support Foundation (GSF) to help connect the hereditary cancer community in a welcoming, digital environment. The group is administered by professionals and patients connected to GSF and aims to provide expert educational materials and to host meaningful discussions around all facets of hereditary cancer. The forum is open to those with positive results, caregivers and loved ones of those with positive results, and those in the medical community who are familiar with the unique needs of someone with hereditary cancer risk. It is not intended to replace any medical care or advice.

When patients receive a positive result for hereditary cancer risk, we often point them to external resources for support. While these resources are well-known and respected, we found that many patients want to connect with others who are going through a similar experience, explains Katie Stoll, executive director of GSF. With this new forum, we can offer people accurate information in a safe and welcoming space with support that goes beyond the counseling appointment.

Inherited pathogenic genetic variants, sometimes called mutations, play a major role in about 5 to 10 percent of all cancers. Better-known pathogenic gene variants include BRCA1 and BRCA2, which increases risk of breast and ovarian cancers, among others. But with mutations in specific genes being linked to more than 50 hereditary cancer syndromes, the hope is that all those affected will feel welcome to join the group.

Carrying the knowledge of being predisposed to cancer can be a burden, or it can be empowering, and often its both, says Nikki McCoy, who will help as an admin on the page, and who is positive for a BRCA1 gene variant. We hope that members feel empowered after visiting the group and that they feel supported and not alone. Community-building can be extremely healing and helpful.

The group is also welcoming of those who may not have had genetic testing but have a strong family history of cancer.

Women and men both have a 50 percent chance to inherit and pass down pathogenic variants. Almost all people who have a pathogenic variant will have a parent who also carries it. Many people who have a pathogenic variant and develop cancer do so at younger ages than the general population.

For more information, visit the Facebook group.

Read the original post:
Genetic Support Foundation of Olympia Announces New Resource for Hereditary Cancer Risk - ThurstonTalk

Recommendation and review posted by Bethany Smith

The global Direct-to-consumer Genetic Testing Marketplace gives detailed Evaluation about all of the important aspects related to the marketplace. The analysis on global Direct-to-consumer Genetic Testing market, offers profound insights about the Direct-to-consumer Genetic Testing market covering all of the crucial characteristics of the market. Moreover, the report provides historical information with prospective prediction over the forecast period. Various important aspects like market trends, revenue development patterns market shares and supply and demand are included in almost all the market research report for every single business. Some of the vital aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players.

The study of different sections of the global market are also Covered in the research report. Along with that, for the prediction periods conclusion of variables such as market size and the competitive landscape of this sector is assessed in the report. On account of the rising globalization and digitization, there are new tendencies coming to the marketplace daily. The research report provides the in-depth analysis of all of these tendencies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2644650&source=atm

In addition, the Direct-to-consumer Genetic Testing market report also supplies the Latest tendencies in the international Direct-to-consumer Genetic Testing market with the assistance of primary as well as secondary research methods. Also, the analysis report on Direct-to-consumer Genetic Testing marketplace gives a wide evaluation of the market which includes market review, manufacturing, manufacturers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of this global Direct-to-consumer Genetic Testing market. On the other hand, the Direct-to-consumer Genetic Testing market report also studies the industry standing for the prediction period. Nevertheless, this can help to increase the advertising opportunities throughout the world in addition to major market providers.

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Direct-to-consumer Genetic Testing market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Direct-to-consumer Genetic Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Direct-to-consumer Genetic Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Direct-to-consumer Genetic Testing market.The following players are covered in this report:23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull GenomesDirect-to-consumer Genetic Testing Breakdown Data by TypeDiagnostic ScreeningPrenatal, Newborn Screening, and Pre-Implantation DiagnosisRelationship TestingDirect-to-consumer Genetic Testing Breakdown Data by ApplicationOnlineOffline

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2644650&source=atm

The Direct-to-consumer Genetic Testing market report provides helpful insights for Every established and advanced players across the world. Additionally the Direct-to-consumer Genetic Testing marketplace report provides accurate analysis for the shifting competitive dynamics. This study report includes a whole analysis of future growth concerning the evaluation of this mentioned prediction interval. The Direct-to-consumer Genetic Testing marketplace report provides a thorough study of the technological growth outlook over time to be aware of the industry growth rates. The Direct-to-consumer Genetic Testing market report also includes innovative analysis of the massive number of unique factors that are fostering or operating as well as regulating the Direct-to-consumer Genetic Testing marketplace development.

A systematized methodology can be used to create a Study on the Global Direct-to-consumer Genetic Testing Sector. For the analysis of market on the terms of research Approaches, these strategies are useful. All the Information Regarding the Products, makers, vendors, clients and even more is covered in research reports. Various important factors like market trends, earnings Growth patterns market stocks and supply and demand are contained in almost all The market research report for every single business. Adaptation of new thoughts and Accepting the latest tendencies are a few the reasons for any markets growth. The Global Direct-to-consumer Genetic Testing market research report gives the deep understanding about the Areas in which the marketplace is impactful.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2644650&licType=S&source=atm

See the article here:
Direct-to-consumer Genetic Testing Market Patents Analysis 2019-2036 - Cole of Duty

Recommendation and review posted by Bethany Smith

The Global Direct-to-Consumer Genetic Testing (DTC-GT) Market analysis report published on Dataintelo.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=33062

The Global Direct-to-Consumer Genetic Testing (DTC-GT) Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Direct-to-Consumer Genetic Testing (DTC-GT) Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Direct-to-Consumer Genetic Testing (DTC-GT) Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=33062

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Direct-to-Consumer Genetic Testing (DTC-GT) Market as:Global Direct-to-Consumer Genetic Testing (DTC-GT) Market Size & Share, by Regions

Global Direct-to-Consumer Genetic Testing (DTC-GT) Market Size & Share, by ProductsOver-the-Counter (OTC) ChannelOnline Channel

Global Direct-to-Consumer Genetic Testing (DTC-GT) Market Size & Share, ApplicationsAncestry-based Genetic TestsHealth and Wellness-based Genetic TestsEntertainment-based Genetic Tests

Key Players24GeneticsAncestry.com LLCDante LabsEasyDNAGenebaseAtlas BiomedFamily Tree DNAMyHeritageMapmygenome

Avail the Discount on this Report @ https://dataintelo.com/ask-for-discount/?reportId=33062

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Go here to read the rest:
Direct-to-Consumer Genetic Testing (DTC-GT) Market | Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2026 -...

Recommendation and review posted by Bethany Smith

A recent Research published on the Global Preimplantation Genetic Testing marketplace provides a comprehensive comprehension of the general prospects of this marketplace. Whats more, the overview of the major findings of this study together with the megatrends affecting the increase of the Preimplantation Genetic Testing market is emphasized in the study. The market definition and introduction is included to assist our readers know the fundamental concepts of the analysis on the Preimplantation Genetic Testing industry.

According to the report, the Preimplantation Genetic Testing marketplace is set to increase the regional commerce analysis together with the major importers and exporters is contained in the research. Additionally, the supply-demand investigation as well as the crucial improvements in the Preimplantation Genetic Testing market are highlighted from the report.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=292

Important Findings of this Report

Segmentation Of this Preimplantation Genetic Testing Market

Competition Tracking

The report also profiles companies operating in the preimplantation genetic testing market, which include Agilent Technologies Inc., Abbott Laboratories, CooperSurgical Inc., Oxford Gene Technology IP, Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Genea Limited, Natera, Inc., Rubicon Genomics, Inc., and CombiMatrix Corporation.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=292

Important Questions Answered In this Preimplantation Genetic Testing Market Report:

Reasons To Buy This Preimplantation Genetic Testing Market Report:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=292

Go here to read the rest:
Preimplantation Genetic Testing Market Anticipated to Grow at a Significant Pace by 2017 to 2022 - Cole of Duty

Recommendation and review posted by Bethany Smith

Singapore and Taiwan to be the first markets in Asia to launch the test kit

SINGAPORE, July 7, 2020 /PRNewswire/ -- Genesis Healthcare Co., Japan's leading genetic testing and research company, today announced the launch of its Asian ancestry focused test kit, GeneLife Generations. The test kit will be officially available to customers from 20 July 2020.

From left to right: GeneLife Generations kit design and mobile application report images showcasing an ethnic mix chart and maternal migration route

Singapore and Taiwan will be the first countries in Asia to launch, followed by other markets in the coming year. GeneLife Generations has been specifically developed for the diversity and richness of the Asian ethnicities and ancestral heritage.

The GeneLife Generations Journey

Through an interactive mobile application, GeneLife Generations will bring users on a personal journey through time to discover what their DNA reveals about their ethnic mix and their lineage, providing unique experiences about possible migration routes from generations ago. This genetic composition analysis service comprehensively predicts the shared genetic composition of ancestors. Along with the genetic ancestral composition analysis, the report will identify origins and migration routes of both maternal and paternal lineages traced back to approximately 150,000 to 270,000 years ago.

Revealing Rich and Diverse Asian Ethnicities

This test kit has been specifically developed for Asian populations, unveiling the various unique ethnic origins through detailed, engaging, and rich contents. These ethnic groups include, but not limited to the following: Chinese Dai, Northern/Southern Han, Singaporean Malay, Vietnamese Kinh, Filipino, Thai, Japanese, Korean, Indonesian, Punjabi, Taiwanese, etc[1].

GeneLife Generations also covers other regions and ethnic groups from different parts of the world including Europe, Africa, and the Americas. Please note that these ethnic groups will be updated and expanded regularly as our science and research develops.

"We are truly proud to be launching GeneLife Generations amongst our suite of consumer DNA test kits," highlighted Michel Mommejat, General Manager, Genesis Healthcare Asia. "We have seen an increasing demand for Ancestry tests that truly represent the Asian population from markets that we operate in, especially Singapore. With over 16 years of R&D applied to genetics and more than 870,000 users who have taken their DNA journey with us, we are in the best position to introduce an ancestry service focused on Asia," he added.

Maternal and Paternal Ancestral Migrations

Our ancestors have travelled across the globe, looking for a place to call home in Asia. GeneLife Generations reveals migrations from maternal and paternal ancestors with an interactive display of their journeys on maps on a smartphone, supported with a dynamic chronological timeline and a range of fun and entertaining information.

The Science Behind GeneLife Generations

Genesis Healthcare is using its specially designed chip for populations in Asia and around the globe, with support from a Micro-array technology platform. For the test, DNA is simply extracted from saliva samples and subjected to genotype calling according to stringent protocols. As more users undertake the genetic test, the panel reference, algorithms, and analysis will be continuously enhanced to provide more refined information as well as reflect latest developments, technology updates and new scientific discoveries.

Story continues

Genesis Healthcare has been actively involved in genetic research and development across multiple domains and has been collaborating in joint research with the National Institute of Genetics in Japan over the years.

Availability & Price

GeneLife Generations will be launching in Singapore on 20 July 2020 at a retail price of SGD199. To celebrate this milestone, GeneLife will be running a pre-release exclusive for the first 500 customers at a discounted price of SGD129. More information can be found on http://www.genelife.asia/product_generations.

About Genesis Healthcare Co. Ltd

Genesis Healthcare Co., Ltd. is a leading biotech company, pioneering genetic research since 2004 and promoting preventive healthcare and wellness through genetic testing. Leveraging more than 16years of genetic research and development, Genesis Healthcare empowers medical institutions and end consumers alike to evolve towards personalized wellness and medicine. Over the years, more than 857,000+ users have trusted GeneLife and Genesis Healthcare to undertake genetic testing. This has allowed the company to validate and improve its science and algorithms over time. Originated in Japan, Genesis Healthcare offers medical, corporate, and consumer services through a range of innovative services across the Asia Pacific region. GeneLife is the direct-to-consumer brand of Genesis Healthcare.

Photo - https://photos.prnasia.com/prnh/20200707/2850185-1

SOURCE Genesis Healthcare Co. Ltd

Go here to read the rest:
Genesis Healthcare Co. launched 'GeneLife Generations', a New Ancestry Kit Designed for the Diversity and Richness of Asian Ethnicities and Ancestral...

Recommendation and review posted by Bethany Smith

A Henrico County-based laboratory company said Tuesday that it is planning to hire about 400 employees as it ramps up its testing capability for the virus that causes COVID-19.

Genetworx, a molecular diagnostic testing lab, said it has immediate hiring needs for jobs such as data entry, lab technicians, tech assistants, project managers, business managers, hiring managers and other work at its facility in the Innsbrook Corporate Center in western Henrico.

We are working 24 hours a day, said Brian ONeill, the companys founder. We have all the equipment to do 100,000 tests a day, and we have the customers. The United States is experiencing a massive demand for COVID-19 testing. We are running three shifts, flat out, and we need to hire at least another 400 people in the next several weeks.

Genetworx now employs about 350 people in the Richmond area, ONeill said. The company also has a laboratory near Philadelphia that is hiring.

It opened its Henrico laboratory in 2013 to do molecular testing for cancer, respiratory illness, genetic testing and other lab work.

With the coronavirus pandemic, the company started offering COVID-19 tests.

We were very busy before this, but we are extremely busy now, he said.

ONeill said jobs would pay between $40,000 and $100,000 a year.

We are willing to train smart people that want to come work for us, he said. We have a program called Re-employing America, and we are targeting people whose jobs were affected by the pandemic, and others. We are also hiring people from the laboratory industry and the health care industry as other labs have seen their work decrease because of less visits to health care.

Genetworx initially leased space in the former Innsbrook Library branch in 2013. Last month, the company leased 19,335 square feet of office space at the Park III building at 4144 Innslake Drive.

ONeill said it now has about 80,000 square feet of space in the two buildings.

See the original post here:
Henrico laboratory hiring 400 as it ramps up COVID-19 testing - Richmond.com

Recommendation and review posted by Bethany Smith

BANGALORE, July 8, 2020 /PRNewswire/ -- Eurofins Clinical Genetics is accredited by NABL & approved by ICMR to perform COVID-19 RT-PCR based testing (ViroSure-19). Eurofins new facility in Peenya, Bangalore is dedicated to Virology testing. Eurofins India has taken steps to support community by starting COVID-19 testing.

The ViroSure-19 test helps clinicians to detect the presence of COVID-19 in human respiratory samples. This diagnostic test offers fast detection of infection and facilitates emergency medical aid to patients before it is too late. Coming from a multinational brand, known for its accuracy and reliability in clinical diagnostics, ViroSure-19 is a sure bet in COVID-19 diagnosis. Today, COVID-19 test is ray of hope to millions of people across the globe and an effective solution like ViroSure-19 becomes a powerful armor to defeat the virus spread.

According to the Eurofins Clinical Genetics BU Head, Mr. Sudhanshu Srivastava,"Eurofins laboratories are fully operational to support patients & families through COVID testing & counseling".The ViroSure-19 is real-time multiplex PCR to detect SARS-CoV-2 in the most efficient way possible. Within a quarter, the team worked rigorously with specialists across organizations team of scientists on building the right test and contributing scientific excellence in infectious disease testing.

Eurofins, has been a very established company with regard to testing services for over 35 years. Eurofins India is now well-prepared to deliver COVID-19 testing across the country. Always recognized for the reliability and accuracy indexes of their products, ViroSure-19has been thoroughly examined by the Eurofins R&D team. As accredited by NABL and approved by ICMR, the ViroSure-19 provided precise results throughout the final testing period. Dr. Sam Balu, Asst. Lab Director, Eurofins Clinical Genetics, said, "I amexpecting a break in the cloud amidst this pandemic situation and hoping for ViroSure-19 diagnosis to help save lives." It will hence help reduce the risk of community spread of the virus amongst Indian metropolitan cities, detect COVID-19 positive cases precisely, and contribute to the fight, the world is pursuing against the global pandemic. Eurofins Clinical Genetics services based on NGS including Exome testing & prenatal testing remain functional throughout lockdown period to serve patients. Eurofins Clinical Genetics has also developed SARS-CoV-2 genome sequencing studies supporting various research organizations to develop preventive strategies against novel corona virus.

About Eurofins

Pioneering in food, environment, pharmaceutical, clinical diagnostics, cosmetic products testing solutions and genetic testing Eurofins remains the global leader with its superior industry standards in quality, accuracy, affordability, and global presence. The number of testing facilities has reached as large as 800 in 50 countries and fast expanding to many more locations. Started as Eurofins Scientific in 1987, the company started to grow with a mission of contributing to a safer and healthier world and never looked back after 2002. Due to unprecedented times, the company's objectives have been directed towards drawing scientific experience to develop a range of SARS-CoV-2 tests in response to the Coronavirus pandemic. To know more about COVID-19 testing at Eurofins India, please connect via mail at salesecgi@eurofins.com or give them a callat +91-95135-20807/ +91-806722-3200.

For details, please visit: https://www.eurofinsclinicalgenetics.co.in/

Media Contact:Eurofins Indiasalesecgi@eurofins.com+91-95135-20807Eurofins Clinical Genetics India Pvt. Ltd.

More here:
Eurofins, the World Leader in Bio-analytical Testing, Launches ViroSure-19, One of the Most Accurat - PharmiWeb.com

Recommendation and review posted by Bethany Smith

Orphan Drug Designation granted to Neurogenes adeno-associated virus vector with engineered transgene encoding the human CLN5 gene

Neurogene Inc., a company founded with a mission to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to adeno-associated virus vector with engineered transgene encoding the human CLN5 gene for patients with CLN5, a form of Batten disease. Batten disease, a common name for a rare class of diseases called neuronal ceroid lipofuscinoses (NCL), affects an estimated 2-4 out of every 100,000 children in the United States.

"CLN5 is a devastating neurodegenerative disease with no FDA approved treatment options," said Rachel McMinn, Ph.D., Neurogenes Founder and Chief Executive Officer. "Receiving Orphan Drug Designation from the FDA is an important regulatory milestone, and we look forward to advancing our gene therapy program into the clinic."

The FDA grants Orphan Drug Designation to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides benefits to drug developers designed to support the development of drugs and biologics for small patient populations with unmet medical needs. These benefits include assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity.

About CLN5Batten disease, also called neuronal ceroid lipofuscinoses (NCLs), is a family of rare and fatal neurodegenerative diseases caused by pathogenic changes in one of a series of genes that result in the accumulation of abnormal storage material across multiple organ systems, including the brain, eye, skin and other tissues. The most prominent effects occur in the brain, where the progressive and inevitable loss of neurons lead to devastating declines in cognitive and motor function in those with Batten disease. The subtype CLN5 is a rare, pediatric-onset and rapidly progressive disease caused by defects in the CLN5 gene. CLN5 disease is characterized by progressive deterioration in intellectual and motor capabilities and vision loss, as well as seizures and death in childhood or adolescence. Diagnosis of the disease is confirmed through genetic testing. Currently, there are no approved disease-modifying therapies available.

About Genetic TestingNeurogene is committed to lowering the barriers of obtaining a genetic diagnosis for patients and has partnered with Invitae to co-sponsor two genetic testing programs. Healthcare providers can order, at no charge, an Invitae Epilepsy panel for any child under the age of eight who has had an unprovoked seizure, or the Detect Lysosomal Storage Diseases panel for patients suspected of having a lysosomal storage disease. Visit https://www.invitae.com/en/sponsored-testing/ for more details.

About Neurogene Inc.Neurogene Inc. is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs are designed to use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy. For more information, visit http://www.neurogene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005106/en/

Contacts

Nikki Kiddnikki.kidd@rturnmktg.com 773-257-7523

Originally posted here:
FDA Grants Orphan Drug Designation to Neurogenes Gene Therapy for the Treatment of CLN5 Batten Disease - Yahoo Finance

Recommendation and review posted by Bethany Smith

Global Point-Of-Care Genetic Testing market study presents an in-depth scenario which is segmented according to manufacturers, product type, applications, and regions. This segmentation will provide deep-dive analysis of the Point-Of-Care Genetic Testing industry for identifying the growth opportunities, development trends and factors limiting the growth of the market. This report offers forecast market information based on past and present Point-Of-Care Genetic Testing industry situations and growth aspects. All the key regions covered in Point-Of-Care Genetic Testing report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Point-Of-Care Genetic Testing market share and market outlook of each region from 2020-2027 are presented in this report. A deep study of Point-Of-Care Genetic Testing market dynamics will help the market aspirants in identifying the business opportunities which will lead to accumulation of revenue. This segment can effectively determine the Point-Of-Care Genetic Testing risk and key market driving forces.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-3138

Initially, the report presents the Point-Of-Care Genetic Testing market overview covering product description, market analysis, market dynamics, opportunities and market share. Secondly, global report conducts a qualitative analysis to present the key manufacturers profile, Point-Of-Care Genetic Testing market share, market size, sales volume, gross margin analysis.

The Point-Of-Care Genetic Testing report is segmented to provide a clear and precise view of the global Point-Of-Care Genetic Testing market statistics and market estimates. Point-Of-Care Genetic Testing report Data represented in the form of graphs, charts, and figures will show the Point-Of-Care Genetic Testing growth rate, volume, target consumer analysis. This report presents the crucial data to all Point-Of-Care Genetic Testing industry aspirants which will facilitate useful business decisions.

Key Players

Cepheid, IQuum, Biocartis, Abbott, Idaho Technologies, ThermoFisher, Roche, Optigene, Lumora are some of the global key players in point-of-care genetic testing. In 2016, Biocartis Idyllas distribution rights were also granted to Thermofisher in the US. The Idylla platform is a fully integrated system enabling laboratories to perform a broad range of applications in oncology and beyond. But in 2014, Iquums Liat Analyzers rights were acquired by Roche Molecular Diagnostics.

The report covers exhaustive analysis on:

The regionalanalysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-3138

The Point-Of-Care Genetic Testing report cover following data points:

Part 1: This part enlists the global Point-Of-Care Genetic Testing market overview, covering the basic market introduction, market analysis by type, applications, and regions. The major Point-Of-Care Genetic Testing producing regions include North America, Europe, Asia-Pacific, Middle-East, and Africa. Point-Of-Care Genetic Testing industry states and outlook (2020-2027) is presented in this part. In addition, Point-Of-Care Genetic Testing market dynamics stating the opportunities, market risk, and key driving forces are studied.

Part 2: This part covers Point-Of-Care Genetic Testing manufacturers profile based on their business overview, product type, and application. Also, the sales volume, Point-Of-Care Genetic Testing product price, gross margin analysis, and Point-Of-Care Genetic Testing market share of each player is profiled in this report.

Part 3 and Part 4: This part presents the Point-Of-Care Genetic Testing competition based on sales, revenue, and market share of each manufacturer. Part 4 covers the Point-Of-Care Genetic Testing market scenario based on regions. Region-wise Point-Of-Care Genetic Testing sales and growth (2015-2019) is studied in this report.

Part 5 and Part 6: These two sections cover the North America and Europes Point-Of-Care Genetic Testing industry by countries. Under this the Point-Of-Care Genetic Testing revenue, market share of the countries like USA, Canada, and Mexico is provided. Under Europe Point-Of-Care Genetic Testing report includes, the countries like Germany, UK, France, Russia, Italy, Russia and their sales and growth is covered.

Part 7, Part 8 and Part 9: These 3 sections covers Point-Of-Care Genetic Testing sales revenue and growth for the regions like Asia-Pacific, South America, Middle East & Africa. Under these regions Point-Of-Care Genetic Testing report covered, the countries like China, Japan, Korea, India, Brazil, Columbia, Argentina, Egypt, Saudi Arabia, Nigeria and South Africa. The sales and growth in these regions are presented in this Point-Of-Care Genetic Testing industry report.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-3138

Part 10 and Part 11: This part depicts the Point-Of-Care Genetic Testing market share, revenue, sales by product type and application. The Point-Of-Care Genetic Testing sales growth seen during 2012-2020 is covered in this report.

Part 12 and Part 13: This part provides forecast information related to Point-Of-Care Genetic Testing market (2020-2027) for each region. The sales channels including direct and indirect Point-Of-Care Genetic Testing marketing, traders, distributors, and future trends are presented in this report.

Part 14 and Part 15: These parts present Point-Of-Care Genetic Testing market key research findings and conclusion, research methodology, and data sources are covered.

Thus, Global Point-Of-Care Genetic Testing report is a complete blend covering all the vital market aspects.

More:
Soaring Demand for Clean-label Food Products to Trigger the Growth of the Point-Of-Care Genetic Testing Market 2017-2027 - Cole of Duty

Recommendation and review posted by Bethany Smith

LOS ANGELES, July 7, 2020 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially life-saving testing options available for both new cancer diagnoses and progression or recurrence of disease. In prostate cancer, testing is a crucial tool that may reveal additional treatment options and/or information for a man's family about their own cancer risk.

Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants). Analysis by The Consistent Testing Terminology Working Group (Working Group) indicates that language disparity is a primary obstacle to patient communication with providers about testing for their specific cancer type. Further, development of consistent language can increase patient understanding and communication, facilitate shared decision making, support value-based care and assure concordance in policy development.

"Both types of testing biomarker testing and genetic testing for inherited cancer risk are important in the care of prostate cancer patients," said Dr. Andrea Miyahira, Director of Global Research and Scientific Communications at PCF. "One example is the very recent approval of medications for men with advanced prostate cancer and certain mutations in their tumor or inherited mutations that would be revealed through testing. Therefore, clear terminology and understanding between patients and providers is all the more vital. PCF supports this valuable collaboration across cancer types."

The Working Group is a consortium of 20 cancer patient advocacy groups representing solid tumor and hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostic companies and testing laboratories. Over the course of many years, multiple activities, led by numerous individual patient advocacy organizations and professional societies have developed the groundwork for this effort. The Working Group has launched a multi-faceted dissemination and communications effort to ensure that its recommendations and supporting materials are widely available among all key stakeholders within the cancer ecosystem, including providers, patient advocacy organizations, guidelines agencies, payers, and policymakers.

In developing its recommendations, the Working Group, first convened in 2019 by LUNGevity Foundation, identified 33 terms related to biomarker, genetic and genomic testing that were being used in patient education and clinical care within the different cancer communities. In many cases, multiple terms were used to describe the same test. Various testing modalities, the source of testing samples, and the multiplicity of gene mutations currently identifiable by testing, were contributing factors in this often-confusing overlap.

In the final analysis, three umbrella descriptor terms emerged as recommendations from the Working Group's milestone exploration: "Biomarker testing" was selected as the preferred term for tests that identify characteristics, targetable findings or other test results originating from malignant tissue and blood; "genetic testing for an inherited mutation" and "genetic testing for inherited cancer risk" were selected as consensus terms for tests used to identify germline (inherited) mutations.

"Far too many patients across all cancer types are still missing out on essential tests for biomarkers and inherited mutations indicating cancer risk," said Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics at Baylor Sammons Cancer Center and Staff Pathologist at Baylor University Medical Center. "With rates of biomarker testing and genetic testing for an inherited mutation at sub-optimal levels for numerous patient populations, patients are not benefiting from biomarker-directed care or not learning about their inherited cancer risk. Confusion around testing terms is a driving factor in this undertesting and ultimately has a detrimental impact on patient care."

"When someone is diagnosed with cancer, they're swept into a whirlwind of bewildering words and complex, pressing decisions. Our Working Group's goal is to help calm that storm of confusion with clear and consistent language that facilitates communication and medical decision-making. A unified voice and message from providers, industry and the patient advocacy community about testing is absolutely vital to optimal cancer care," said Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity Foundation.

An abstract on the Working Group's recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library. The White Paper can be viewed in its entirety athttp://www.commoncancertestingterms.org/.

About LUNGevity Foundation LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the diseasewhile promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivorsand those who help them live better and longer lives.

Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our visiona world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization. Please visit http://www.LUNGevity.org to learn more.

About the Prostate Cancer Foundation The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has raised more than $830 million in support of cutting-edge research by more than 2,200 research projects at 220 leading cancer centers in 22 countries around the world. Thanks in part to PCF's commitment to ending death and suffering from prostate cancer, the death rate is down more than 50% and countless more men are alive today as a result. PCF research now impacts more than 73 forms of human cancer by focusing on immunotherapy, the microbiome, and food as medicine. For more information, visit PCF.org.

Media Contact: Donald Wilson Prostate Cancer Foundation (310) 428-4730 press@pcf.org

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-prostate-cancer-foundation-collaboration-with-pan-cancer-consortium-clarifies-and-promotes-consistent-use-of-common-terms-for-biomarker-and-germline-genetic-testing-301088974.html

SOURCE Prostate Cancer Foundation

Read the original post:
The Prostate Cancer Foundation Collaboration With Pan-Cancer Consortium Clarifies And Promotes Consistent Use Of Common Terms For Biomarker And...

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, July 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad’s market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

We are excited to offer this innovative new tool for physicians and patients to provide best-in-class pre-test education solutions that we can supplement with live sessions when necessary,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. Myriad is highly focused on making the screening and testing process as streamlined as possible for healthcare providers and the implementation of this new technology will give their patients access to unparalleled online genetic education and support tools. This is especially important in the current environment with COVID-19 where patients may not be returning to the clinic setting and pre-test education can be particularly helpful as they work remotely with the healthcare provider to determine if testing is right for them.”

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight® and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

About OptraHEALTH: OptraHEALTH is focused on improving outcomes for consumers and leading Life Sciences and Healthcare organizations by utilizing a next-generation Artificial Intelligence Platform. OptraHEALTH’s flagship product GeneFAX is an AI-powered knowledge platform for genetic health and is available as a web plugin or mobile application.

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, Prolaris and riskScore are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to implementation of this new technology giving patients access to unparalleled online genetic education and support tools; plans to launch the Gene chatbot for its ForeSight® and Prequel prenatal tests and for hereditary cancer testing in oncology later this calendar year; details of the functionality of the Gene chatbot; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Excerpt from:
Myriad Announces Partnership with OptraHEALTH to Deliver "Gene(TM)" a New AI Based Information Tool for Hereditary Cancer Patients |...

Recommendation and review posted by Bethany Smith